Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer

NCT05855811 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT05855811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05855811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Recruiting
Start date
July 26, 2023
Completion date
March 26, 2029
Enrollment
400 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary cancer, recurrent cancer, second cancer